| dc.relation | 1. World Health Organization. WHO report on the
global tobacco epidemic, 2008: the MPOWER
package. Geneva: World Health Organization;
2008.
2. Pan American Health Organization. Health in
the Americas. 2002 edition. Washington DC: Pan
American Health Organization; 2002.
3. Hodgson TA, Meiners MR. Cost-of-illness methodology:
a guide to current practices and procedures.
Milbank Mem Fund Q 1982; 60:429-62.
4. Yang MC, Fann CT, Wen CP, Cheng TY. Smoking attributable
medical expenditures, years of potential
life lost, and the cost of premature death in Taiwan.
Tob Control 2005; 14:62-70.
5. Xiao X, Robson L, Single E, Rehm J, Paul J. The economic
consequences of smoking in Ontario. Pharmacol
Res 1999; 39:185-91.
6. Ruff LK, Volmer T, Nowak D, Meyer A. The economic
impact of smoking in Germany. Eur J Respir
Dis 2000; 16:377-8.
7. Neubauer S, Welte R, Beiche A, Koenig H-H, Buesch
K, Leidl R. Mortality, morbidity and costs attributable
to smoking in Germany: update and a 10-year
comparison. Tob Control 2006; 15:464-71.
8. John RM, Sung H-U, Max W. Economic cost of
tobacco use in India, 2004. Tob Control 2009; 18:
138-43.
9. Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating
costs in cost-effectiveness analysis. In:
Gold MR, Siegel JE, Russel LB, Weinstein MC, editors.
Cost-effectiveness in health and medicine.
2nd Ed. New York: Oxford University Press; 1996. p.
176-213.
10. Garber AM, Weinstein MC, Torrance GW, Kamlet
MS. Theoretical foundations of cost-effectiveness
analysis. In: Gold MR, Siegel JE, Russel LB, Weinstein
MC, editors. Cost-effectiveness in health and
medicine. 2nd Ed. New York: Oxford University
Press; 1996. p. 25-53.
11. Kobelt G. A economia da saúde: uma introdução
à avaliação econômica em saúde. 2a Ed. London:
Office of Health Economics; 2008.
12. Segel JE. Cost-of-illness studies: a primer. Research
Triangle Park: RTI-UNC Center of Excellence in
Health Promotion Economics; 2006.
13. Rubenstein LM, Chrischilles EA, Voelker MD. The
impact of Parkinson’s disease on health status,
health expenditures, and productivity: estimates
from the National Medical Expenditure Survey.
Pharmacoeconomics 1997; 12:486-98.
14. Swensen A, Birnbaum HG, Secnik K, Marynchenko
M, Greenberg P, Claxton A. Attention deficit/hyperactivity
disorder: increased costs for patients
and their families. J Am Acad Child Adolesc Psychiatry
2003; 42:1415-23.
15. Centers of Disease Control and Prevention.
Smoking-attributable mortality, years of potential
life lost, and productivity losses – United States,
1997-2001. MMWR Morb Mortal Wkly Rep 2005;
54:625-8.
16. Barnes PJ, Jonsson B, Klim JB. The costs of asthma.
Eur Resp J 1996; 9:636-42.
17. Luce BR, Schweitzer SO. Smoking and alcohol
abuse: a comparison of their economic consequences.
N Engl J Med 1978; 298:569-71.
18. Office of Technology Assessment, U.S. Congress.
Smoking related deaths and financial costs. Washington
DC: U.S. Government Printing Office; 1985.
19. Shultz JM, Novotny TE, Rice DP. Quantifying the
disease impact of cigarette smoking with SAMMEC
II software. Public Health Rep 1991; 106:326-33.
20. Oster G, Colditz GA, Kelly NL. The Economic costs
of smoking and benefits of quitting for individual
smokers. Prev Med 1994; 13:377-89.
21. Leu RE, Schaub T. More on impact of smoking on
medical care expenditures. Soc Sci Med 1985; 21:
825-7.
22. Manning WG, Keeler EB, Newhouse JP, Sloss EM,
Wasserman J. The taxes of sin: do smokers and
drinkers pay their way? JAMA 1989; 261:1604-9.
23. Manning WG, Keeler EB, Newhouse JP, Sloss EM,
Wasserman J. The cost of poor health habits. Cambridge:
Harvard University Press; 1991.
24. Collins DJ, Lapsley H. Estimating and disaggregating
the social costs of tobacco. In: Abedian I, van
der Merwe R, Wilkins N, Jha P, editors. The economics
of tobacco control: towards an optimal
policy mix. Cape Town: Applied Fiscal Research
Centre, University of Cape Town; 1998.
25. World Bank. Curbing the epidemic: governments
and the economics of tobacco control. Washington
DC: International Bank for Reconstruction and
Development/World Bank; 1999.
26. Garfinkel L. Selection, follow-up, and analysis in
the American Cancer Society prospective studies. J
Natl Cancer Inst Monogr 1985; 67:49-52.
27. Garfinkel L, Stellman SD. Smoking and lung cancer
in women: findings in a prospective study. Cancer
Res 1998; 48:6951-5.
28. Stellman SD, Garfinkel. Smoking habits and tar
levels in a new American Cancer Society prospective
study of 1.2 million men and women. J Natl
Cancer Inst 1986; 76:1057-63.
29. Anderson RN, Miniño AM, Hoyert DL, Rosenberg
HM. Comparability of cause of death between
ICD-9 and ICD-10: preliminary estimates. Natl Vital
Stat Rep 2001; 49:1-32.
30. Levin ML. The occurrence of lung cancer in man.
Acta Unio Int Contra Cancrum 1953; 9:531-41.
31. Hanley J. A heuristic approach to the formulas for
population attributable fraction. J Epidemiol Community
Health 2001; 55:508-14.
32. Centers for Disease Control and Prevention. Perspectives
in disease prevention and health promotion.
Smoking-attributable mortality and years
of potential life lost-United States, 1984. MMWR
Morb Mortal Wkly Rep 1987; 36:693-7.
33. Szwarcwald CL, Viacava F, Vasconcellos MTL, Leal
MC, Azevedo LO, Queiroz RSB, et al. Pesquisa
Mundial de Saúde 2003: o Brasil em números.
Radis 2004; (23):14-33.
34. Gajalakshmi CK, Jha P, Ranson K, Nguyen S. Global
patterns of smoking and smoking-attributable
mortality. In: Jha P, Chaloupka F, editors. Tobacco
control in developing countries. New York: Oxford
University Press; 2000. p. 9-39. | |
